Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Authors:

Published: 2023-11-01

DOI: 10.1097/hs9.0000000000000987

Source: Full article

---

Abstract

No abstract found.